Lista de obras - Marina Elena Cazzaniga - Dominio Público Uruguay

A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates

scientific article published on 01 May 1995

A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.

artículo científico publicado en 1995

Acute dyspnea due to right phrenic palsy during infusional chemotherapy

artículo científico publicado en 2004

Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2

scientific article published on 01 February 1997

Adjuvant systemic treatment of early breast cancer: the NORA study.

artículo científico publicado en 2006

Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study

scientific article published on 30 August 2007

Bisphosphonates and metastatic bone disease.

artículo científico publicado en 2006

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.

artículo científico publicado en 2015

Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study

artículo científico publicado en 2006

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

artículo científico publicado en 2019

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.

artículo científico publicado en 2017

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

artículo científico

Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.

artículo científico publicado en 2016

Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone.

artículo científico publicado en 1994

Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

artículo científico publicado en 2017

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

artículo científico publicado en 2015

From the trastuzumab era to new target therapies: beyond revolution.

artículo científico publicado en 2007

Gene expression profiling in breast cancer: a clinical perspective.

artículo científico

Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.

artículo científico publicado en 2015

Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation?

artículo científico publicado en 2004

Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract

artículo científico publicado en 1993

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

artículo científico publicado en 2020

In reply to Kadri Altundag.

artículo científico publicado en 2016

Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer

artículo científico publicado en 2012

Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.

artículo científico publicado en 2010

Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study

artículo científico publicado en 2014

Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers

artículo científico publicado en 2013

Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success

scientific article published on 07 May 2019

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?

artículo científico publicado en 2017

Metronomic chemotherapy for advanced breast cancer patients

artículo científico publicado en 2016

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.

scientific article published on 17 October 2016

Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.

artículo científico publicado en 2015

Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone

artículo científico publicado en 1995

Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials

artículo científico publicado en 2017

Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study.

artículo científico publicado en 2009

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

artículo científico publicado en 2018

Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project

artículo científico publicado en 2018

Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.

artículo científico publicado en 2014

Prediction of recurrence in operable breast cancer by postoperative changes in prolactin secretion

artículo científico publicado en 1995

Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve.

artículo científico publicado en 2018

Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.

artículo científico publicado en 2008

The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma

artículo científico publicado en 2006

Venous thromboembolism and cancer: new issues for an old topic.

artículo científico publicado en 2003

Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study.

artículo científico publicado en 2003

Lista de obras de Marina Elena Cazzaniga

A randomized study of low-dose subcutaneous interleukin-2 plus melatonin versus supportive care alone in metastatic colorectal cancer patients progressing under 5-fluorouracil and folates

A randomized study of neuroimmunotherapy with low-dose subcutaneous interleukin-2 plus melatonin compared to supportive care alone in patients with untreatable metastatic solid tumour.

Acute dyspnea due to right phrenic palsy during infusional chemotherapy

Acute effects of pamidronate administration on serum levels of interleukin-6 in advanced solid tumour patients with bone metastases and their possible implications in the immunotherapy of cancer with interleukin-2

Adjuvant systemic treatment of early breast cancer: the NORA study.

Adjuvant treatment of early breast cancer: do the St Gallen recommendations influence clinical practice? Results from the NORA study

Bisphosphonates and metastatic bone disease.

Demographic, tumor and clinical features of clinical trials versus clinical practice patients with HER2-positive early breast cancer: results of a prospective study.

Diagnosis, Management and Clinical Outcome of Bone Metastases in Breast Cancer Patients: Results from a Prospective, Multicenter Study

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting

Dose intensity and efficacy of the combination of everolimus and exemestane (EVE/EXE) in a real-world population of hormone receptor-positive (ER+/PgR+), HER2-negative advanced breast cancer (ABC) patients: a multicenter Italian experience.

Efficacy and safety of Everolimus and Exemestane in hormone-receptor positive (HR+) human-epidermal-growth-factor negative (HER2-) advanced breast cancer patients: New insights beyond clinical trials. The EVA study

Efficacy and safety of vinorelbine-capecitabine oral metronomic combination in elderly metastatic breast cancer patients: VICTOR-1 study.

Efficacy of the concomitant administration of the pineal hormone melatonin in cancer immunotherapy with low-dose IL-2 in patients with advanced solid tumors who had progressed on IL-2 alone.

Everolimus Plus Exemestane in Advanced Breast Cancer: Safety Results of the BALLET Study on Patients Previously Treated Without and with Chemotherapy in the Metastatic Setting.

FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.

From the trastuzumab era to new target therapies: beyond revolution.

Gene expression profiling in breast cancer: a clinical perspective.

Genetic determinants of chronic oxaliplatin-induced peripheral neurotoxicity: a genome-wide study replication and meta-analysis.

Gilbert's syndrome and fluorouracil toxicity in colorectal cancer patients: which correlation?

Immunotherapy with subcutaneous low-dose interleukin-2 and the pineal indole melatonin as a new effective therapy in advanced cancers of the digestive tract

Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence

In reply to Kadri Altundag.

Incidence of atypical acute nerve hyperexcitability symptoms in oxaliplatin-treated patients with colorectal cancer

Isotretinoin plus clindamycin seem highly effective against severe erlotinib-induced skin rash in advanced non-small cell lung cancer.

Long-term course of oxaliplatin-induced polyneuropathy: a prospective 2-year follow-up study

Male breast cancer: clinical features and multimodal treatment in a retrospective survey analysis at Italian centers

Management of toxicities associated with targeted therapies for HR-positive metastatic breast cancer: a multidisciplinary approach is the key to success

Metronomic Chemotherapy in Triple-Negative Metastatic Breast Cancer: The Future Is Now?

Metronomic chemotherapy for advanced breast cancer patients

Metronomic chemotherapy with oral vinorelbine (mVNR) and capecitabine (mCAPE) in advanced HER2-negative breast cancer patients: is it a way to optimize disease control? Final results of the VICTOR-2 study.

Metronomic oral vinorelbine in advanced breast cancer and non-small-cell lung cancer: current status and future development.

Modulation of cancer endocrine therapy by melatonin: a phase II study of tamoxifen plus melatonin in metastatic breast cancer patients progressing under tamoxifen alone

Nab-Paclitaxel in Advanced HER2-negative Breast Cancer Patients: Efficacy and Safety Beyond Clinical Trials

Neo-adjuvant exemestane in elderly patients with breast cancer: a phase II, multicentre, open-label, Italian study.

Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience

Pan-European Expert Meeting on the Use of Metronomic Chemotherapy in Advanced Breast Cancer Patients: The PENELOPE Project

Pharmacogenetic interaction analysis of VEGFR-2 and IL-8 polymorphisms in advanced breast cancer patients treated with paclitaxel and bevacizumab.

Prediction of recurrence in operable breast cancer by postoperative changes in prolactin secretion

Risk stratification of oxaliplatin induced peripheral neurotoxicity applying electrophysiological testing of dorsal sural nerve.

Targeted therapies for the treatment of breast cancer in the post-trastuzumab era.

The extension of disease is associated to an increased risk of venous thromboembolism (VTE) in patients with gastrointestinal (GI) carcinoma

Venous thromboembolism and cancer: new issues for an old topic.

Vinorelbine and carboplatin in inoperable non-small cell lung cancer: a monoinstitutional phase II study.